Celgene partners with UK's Oxford Sciences Innovation

12 January 2017

US biopharmaceutical company Celgene (Nasdaq: CELG) will partner with Oxford Sciences Innovation (OSI), taking certain option rights related to therapeutic developments in the field of cancer and immune-inflammatory diseases.

OSI is an investment fund set up to provide capital and scaling expertise to businesses, including many driven by intellectual property developed at Oxford University. Pharmaceutical investments support research undertaken in the life sciences and medical sciences divisions of the world-renowned university.

Life sciences investment lead at OSI Dr Andrew McLean stated: “This is an incredibly exciting opportunity for OSI. The medical sciences work in Oxford pushes the frontier of our understanding of biological systems and disease.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK